BenevolentAI

BenevolentAI is a pioneering leader in the application of advanced AI to drug discovery and development. Their slogan "Accelerate scientific breakthroughs with AI" encapsulates their mission to increase the probability of success and reduce timelines in drug development, which currently faces a failure rate exceeding 90%. The company’s proprietary Benevolent PlatformTM is a validated AI drug discovery technology, covering Target Identification, Chemistry, and Drug Repurposing, enabling them to deliver across the entire R&D lifecycle. Founded in 2013, BenevolentAI's expertise spans AI, Big Data, Biotechnology, Pharmaceutical, and Machine Learning. Their headquarters are in London, United Kingdom. Their most recent investment was a $90.00M Private Equity Round by Temasek Holdings on 17th September 2019. This funding will likely further their efforts in advancing AI-driven solutions in the pharmaceutical and biotechnology sectors.